Seeking Alpha

Threshold Pharmaceuticals (THLD) says it will be providing additional details next week from a...

Threshold Pharmaceuticals (THLD) says it will be providing additional details next week from a Phase IIb clinical trial for its TH-302 pancreatic cancer drug candidate during the American Association for Cancer Research annual meeting in Chicago. Shares +1.4% AH.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|